Hippocrates Research Foundation
Informed Patient Series — Alzheimer's Disease, Booklet 2 of 3
A standard Alzheimer's diagnosis tells you what is happening but not why. A neurologist will typically confirm the presence of cognitive decline through office-based testing, order an MRI to rule out strokes or tumors, and perhaps refer for amyloid PET imaging. You leave with a diagnosis and a prescription for donepezil.
This approach misses the most important question: What is driving this disease in this particular patient?
As Booklet 1 explained, Alzheimer's involves at least fifteen interacting pathways — from mitochondrial dysfunction and brain insulin resistance to neuroinflammation, blood-brain barrier breakdown, and infectious burden. Each patient has a different combination of contributing factors. Treatment that does not identify which pathways are impaired in a specific individual cannot be optimally effective.
This booklet covers the full spectrum of testing — from standard neurological assessments to advanced functional medicine panels that most neurologists do not order. The goal is not to replace your physician's workup but to expand it dramatically, transforming a diagnosis of despair into a roadmap for targeted intervention.
Baseline cognitive testing establishes the severity of impairment and provides objective measurements that can be tracked over time to assess treatment response.
Mini-Mental State Examination (MMSE): The most widely used screening tool, scored from 0–30. Scores of 24–30 are considered normal, 20–23 suggest mild impairment, 10–19 moderate, and below 10 severe. While useful for staging, the MMSE has limited sensitivity for detecting early decline and does not assess executive function well.
Montreal Cognitive Assessment (MoCA): More sensitive than the MMSE for detecting mild cognitive impairment (MCI), particularly in educated patients who may score normally on the MMSE despite meaningful decline. The MoCA assesses attention, concentration, executive function, memory, language, visuospatial skills, abstraction, and orientation. A score below 26 suggests impairment. This is the preferred screening tool for detecting early disease.
CNS Vital Signs: A computerized neurocognitive assessment battery that provides objective, reproducible measurements across multiple cognitive domains including memory, processing speed, executive function, reaction time, and complex attention. Because it is computerized and standardized, it minimizes examiner variability and produces domain-specific scores that can be compared precisely over time. This makes it particularly valuable for monitoring treatment response — even small improvements in specific domains can be objectively documented.
MRI (Magnetic Resonance Imaging): Structural MRI reveals brain atrophy, hippocampal volume loss, white matter changes, and evidence of vascular disease or prior strokes. While it cannot diagnose Alzheimer's directly, it provides important structural information and rules out other treatable causes of cognitive decline including tumors, normal pressure hydrocephalus, and subdural hematomas.
Volumetric MRI can measure hippocampal volume quantitatively, providing a more sensitive measure of atrophy than visual inspection alone. Serial volumetric measurements can track the rate of brain volume loss over time.
CT Scan: Less detailed than MRI but useful for patients who cannot undergo MRI (those with certain cardiac devices or severe claustrophobia). Primarily used to rule out structural abnormalities.
FDG-PET (Fluorodeoxyglucose Positron Emission Tomography): This is arguably the single most important imaging study in Alzheimer's disease because it directly measures glucose metabolism — the brain's energy utilization. FDG-PET can detect hypometabolism in characteristic patterns 10–15 years before clinical symptoms appear, making it the earliest available imaging biomarker.
The classic Alzheimer's pattern shows reduced glucose uptake in the posterior cingulate, temporal, and parietal regions. This directly reflects the "Type 3 Diabetes" discussed in Booklet 1 — the brain's inability to use glucose effectively. A normal FDG-PET in a patient with cognitive complaints significantly reduces the likelihood of Alzheimer's disease and should prompt evaluation for other causes.
Amyloid PET: Detects amyloid plaque burden in the brain using radioactive tracers that bind to amyloid deposits. A positive amyloid PET confirms the presence of plaques but does not indicate the cause of the accumulation. Approximately 30% of cognitively normal elderly individuals have positive amyloid PET scans — meaning plaques are present without symptoms. This underscores the point made in Booklet 1: plaques are a marker of failed clearance, not a direct measure of disease activity.
Tau PET: A newer imaging modality that detects tau tangles. Tau burden correlates more closely with cognitive symptoms than amyloid burden, making tau PET potentially more useful for staging disease severity and tracking progression.
SPECT (Single Photon Emission Computed Tomography): Measures cerebral blood flow rather than metabolism or protein deposits. Less detailed than PET but more widely available and less expensive. Can identify regions of hypoperfusion that correspond to the cerebral blood flow deficits described in Booklet 1. Some functional medicine practitioners, notably Dr. Daniel Amen, have used SPECT imaging extensively to guide treatment decisions and monitor response to interventions targeting cerebral perfusion. While SPECT lacks the resolution of PET imaging, it provides clinically useful information about regional blood flow patterns and can be repeated serially to track improvement.
The tests in this section are rarely ordered by conventional neurologists but are essential for identifying the specific metabolic, immune, and inflammatory contributors driving disease in each individual. This is where the testing paradigm shifts from confirming a diagnosis to building a treatment plan.
Fasting Insulin: This is one of the most important and most overlooked blood tests in Alzheimer's evaluation. Standard metabolic panels measure fasting glucose and hemoglobin A1c — both of which remain normal until insulin resistance is advanced. Fasting insulin rises years before glucose becomes abnormal, making it an earlier and more sensitive marker.
Optimal fasting insulin is below 5 μIU/mL. Levels above 8–10 suggest clinically significant insulin resistance that may be actively contributing to brain glucose hypometabolism. Many patients with normal fasting glucose have markedly elevated insulin levels — their pancreas is compensating by producing more insulin, masking the underlying resistance.
Hemoglobin A1c: Reflects average blood glucose over 2–3 months. While less sensitive than fasting insulin for detecting early insulin resistance, HbA1c above 5.5% warrants attention in the context of cognitive decline. Optimal is below 5.3%.
HOMA-IR (Homeostatic Model Assessment for Insulin Resistance): Calculated from fasting glucose and fasting insulin, HOMA-IR provides a single number reflecting overall insulin resistance. Values above 2.0 suggest clinically significant resistance.
Continuous Glucose Monitor (CGM): A wearable device that measures interstitial glucose every 5–15 minutes, revealing glucose variability patterns invisible to standard testing. Post-meal glucose spikes above 140 mg/dL damage endothelial cells, promote inflammation, and accelerate metabolic disease — even in patients with normal fasting glucose and HbA1c. CGMs are increasingly accessible and can guide dietary modifications with immediate, objective feedback.
High-Sensitivity C-Reactive Protein (hs-CRP): A marker of systemic inflammation. Optimal is below 1.0 mg/L. Elevated hs-CRP reflects inflammatory processes that contribute to neuroinflammation, BBB breakdown, and accelerated neurodegeneration. It also helps assess cardiovascular risk, which is closely linked to cerebrovascular health.
Homocysteine: Elevated homocysteine is an independent risk factor for both cardiovascular disease and cognitive decline. It promotes endothelial damage, BBB breakdown, and direct neurotoxicity. Optimal is below 7 μmol/L. Elevated levels are often correctable with methylated B vitamins (methylfolate, methylcobalamin, P5P) — one of the simplest and most effective interventions available.
Erythrocyte Sedimentation Rate (ESR): Another general inflammation marker that, combined with hs-CRP, provides a broader picture of the systemic inflammatory burden.
Vitamin D (25-hydroxyvitamin D): Vitamin D deficiency is extremely common in Alzheimer's patients. Vitamin D acts as a neurosteroid, supporting neuronal growth, amyloid clearance, and immune regulation. Optimal levels are 60–80 ng/mL — well above the conventional "normal" range of 30+.
Omega-3 Index: Measures the percentage of EPA and DHA in red blood cell membranes, reflecting long-term omega-3 status. An Omega-3 Index above 8% is associated with reduced dementia risk, lower inflammation, and improved neuronal membrane fluidity. Most Americans are below 4%.
RBC Magnesium: More accurate than serum magnesium for assessing true magnesium status. Magnesium is critical for over 300 enzymatic reactions including ATP production, neurotransmitter synthesis, and NMDA receptor regulation. Deficiency is common and contributes to inflammation, insulin resistance, and neuronal hyperexcitability.
Copper/Zinc Ratio: Elevated free copper relative to zinc is neurotoxic and has been directly implicated in Alzheimer's pathology by multiple research groups. The copper-to-zinc ratio should be approximately 1:1. Many Alzheimer's patients show significantly elevated copper with correspondingly low zinc.
The Cyrex Alzheimer's LINX panel is a specialized blood test that evaluates immune reactivity to factors specifically implicated in Alzheimer's pathology. Unlike standard testing that looks for the disease after it has developed, the LINX panel identifies the upstream immune and environmental triggers that may be driving the disease process.
The panel tests for antibodies against multiple categories of antigens relevant to Alzheimer's disease:
Neuronal Antigens: Antibodies against brain-specific proteins including tau, amyloid-beta, neurofilaments, and myelin basic protein. The presence of these antibodies indicates that the immune system is actively attacking brain tissue — autoimmune neurodegeneration that may be treatable by identifying and removing the triggers.
Blood-Brain Barrier Proteins: Antibodies against tight junction proteins (occludin, claudins, zonulin) and BBB structural components. Elevated antibodies confirm BBB breakdown and provide objective evidence for one of the fifteen pathways described in Booklet 1.
Pathogen-Associated Antigens: Antibodies against HSV-1, P. gingivalis, and other organisms implicated in Alzheimer's. This allows targeted antimicrobial or antiviral therapy rather than empiric treatment — valacyclovir for HSV-1 reactivation, targeted periodontal therapy for P. gingivalis, or specific antibiotics for other identified pathogens.
Food and Environmental Antigens: Cross-reactive antibodies that may contribute to neuroinflammation through molecular mimicry — where immune responses to food proteins or environmental antigens inadvertently attack brain tissue because of structural similarities.
The LINX panel transforms Alzheimer's treatment from a generic protocol into a personalized, targeted intervention strategy based on each patient's specific immune profile. A patient with high antibodies against HSV-1 antigens might receive valacyclovir as part of their protocol, while a patient with elevated P. gingivalis antibodies would prioritize aggressive periodontal treatment and targeted antimicrobials. Without this testing, clinicians are guessing about which infectious and immune triggers to address.
The panel also provides prognostic information. Patients with widespread cross-reactivity across multiple antigen categories may require more aggressive and comprehensive treatment than those with isolated findings. Serial testing at 6–12 month intervals can document whether interventions are reducing the immune burden — providing objective evidence that the treatment plan is working at the molecular level, even before cognitive improvements become apparent on standardized tests.
It is worth noting that the Cyrex LINX panel is not available through standard commercial laboratories. It must be ordered through a licensed healthcare provider who has established an account with Cyrex Laboratories. Patients interested in this testing should ask their physician or seek a functional medicine provider familiar with the panel.
The Lymphocyte MAP provides a comprehensive analysis of immune cell populations, including absolute counts and percentages of CD4+ helper T cells, CD8+ cytotoxic T cells, natural killer (NK) cells, B cells, and regulatory T cells (Tregs). In Alzheimer's patients, this panel can reveal immune dysregulation that contributes to neuroinflammation — including imbalanced CD4:CD8 ratios, reduced NK cell function, or deficient regulatory T cell populations that normally prevent autoimmune reactions against neural tissue.
The Lymphocyte MAP is particularly valuable when combined with the LINX panel. The LINX identifies what the immune system is reacting to, while the Lymphocyte MAP reveals how the immune system itself is functioning. Together, they provide a complete picture of the immune contribution to neurodegeneration.
This testing is also valuable for guiding immune-modulating interventions discussed in Booklet 3, including AC-11 (Uncaria tomentosa CAE, which can improve CD4:CD8 ratios and promote Th1 polarization) and low-dose naltrexone (which modulates overall immune function through opioid receptor antagonism). Serial Lymphocyte MAP testing can document whether these interventions are producing measurable changes in immune cell populations.
The following additional Cyrex panels provide complementary information that helps build a complete picture of the immune, gut, and environmental factors contributing to neurodegeneration.
Array 2 (Intestinal Permeability): Measures antibodies against tight junction proteins (occludin, zonulin) and lipopolysaccharide (LPS), directly assessing "leaky gut." Intestinal permeability often parallels blood-brain barrier permeability — they share similar tight junction mechanisms. A positive Array 2 result suggests that gut-derived inflammatory molecules are entering the bloodstream and potentially reaching the brain. Addressing intestinal permeability through dietary modification, targeted supplementation (L-glutamine, zinc carnosine, colostrum), and gut microbiome restoration is a foundational step in reducing the neuroinflammatory burden.
Array 3 (Wheat/Gluten Sensitivity): Identifies immune reactivity to wheat and gluten peptides across a comprehensive panel of antigens, not just the limited gliadin and transglutaminase markers used in standard celiac testing. Gluten sensitivity can drive systemic inflammation and neuroinflammation even in patients without celiac disease. Some researchers have identified cross-reactivity between gluten peptides and neural tissue antigens, providing a direct mechanism by which dietary gluten could contribute to autoimmune neurodegeneration in susceptible individuals.
Array 4 (Food Sensitivity): Identifies immune reactions to common dietary proteins including dairy, egg, soy, corn, and various grains. Chronic low-grade immune activation from food sensitivities contributes to systemic inflammation that reaches the brain. Identifying and eliminating trigger foods can meaningfully reduce the inflammatory burden without medication.
Array 5 (Autoimmune Reactivity): Screens for predictive antibodies associated with multiple autoimmune conditions. This is particularly important because autoimmune processes may be contributing to neurodegeneration in ways that are not apparent from standard testing. Patients with elevated predictive antibodies may benefit from immune-modulating interventions before overt autoimmune disease develops.
Array 10 (Chemical Sensitivity): Measures immune reactions to environmental chemicals including BPA, heavy metals (mercury, lead, arsenic), formaldehyde, and mold toxins (aflatoxins, ochratoxin, trichothecenes). Toxic exposure is one of the drivers of Alzheimer's disease in Bredesen's classification system — his "Type 3" or toxic subtype. Patients with high toxic burden may require specific detoxification protocols before other interventions can be fully effective.
Array 12 (Pathogen-Associated Immune Reactivity): Identifies immune responses to a broader range of bacteria, viruses, parasites, and fungi beyond those covered in the LINX panel. This is particularly useful for identifying stealth infections that may be contributing to chronic immune activation and neuroinflammation.
Array 20 (Blood-Brain Barrier Permeability): Directly assesses BBB integrity through measurement of antibodies against brain endothelial cell proteins and barrier-specific antigens. This is one of the most directly relevant panels for Alzheimer's evaluation, as BBB breakdown is a critical pathway in the disease process. Results can be tracked serially to monitor whether interventions are restoring barrier integrity.
Array 22 (Irritable Bowel/SIBO): Evaluates immune markers associated with small intestinal bacterial overgrowth (SIBO) and gut-brain axis disruption. SIBO produces excessive amounts of bacterial metabolites that can cross both the intestinal barrier and the BBB, contributing to neuroinflammation. Treatment of identified SIBO can reduce one source of inflammatory input to the brain.
Dr. Dayan Goodenowe's ProdromeScan is a blood-based assay that measures critical lipid biomarkers including plasmalogen levels, phospholipid species, and other membrane-related compounds. Because plasmalogen depletion occurs early in the disease process — often years before cognitive symptoms — ProdromeScan serves as both a risk assessment tool and a treatment target.
Dr. Goodenowe's research, using longitudinal data from the Framingham Heart Study and other major cohorts, demonstrated that individuals with the lowest plasmalogen levels had the highest risk of developing dementia over the following decade. This makes ProdromeScan particularly valuable as a screening tool for patients with family history of Alzheimer's or other risk factors who want to assess their status before symptoms develop.
Patients with documented plasmalogen deficiency can be treated with targeted plasmalogen precursor supplementation (ProdromeNeuro, ProdromeGlia) and monitored with serial ProdromeScan testing to verify that levels are improving. This creates a test-treat-retest cycle that is the hallmark of precision medicine.
For patients implementing ketogenic interventions (covered in Booklet 3), a fingerstick ketone monitor provides immediate feedback on whether the brain's alternative fuel system is being activated. Blood beta-hydroxybutyrate levels of 0.5–3.0 mmol/L indicate nutritional ketosis — the range where ketone delivery to the brain becomes therapeutically significant. These monitors cost $30–$50 and test strips approximately $1 each, making this an accessible and practical way to confirm that dietary changes or MCT oil supplementation are producing measurable ketone levels.
Not every patient needs every test listed in this booklet. The optimal testing strategy depends on the stage of disease, the clinical presentation, insurance coverage, and financial resources.
For any patient with cognitive decline or MCI, the following represents a reasonable minimum: MoCA or CNS Vital Signs for cognitive baseline, MRI for structural assessment, fasting insulin and HbA1c for metabolic status, hs-CRP and homocysteine for inflammation, vitamin D, omega-3 index, APOE genotyping, and a sleep study. This panel can be obtained through most primary care physicians and provides enough information to begin targeted intervention.
When resources allow, adding the Cyrex LINX panel, Lymphocyte MAP, Arrays 2 and 20 (gut and BBB permeability), and ProdromeScan provides dramatically more information for treatment personalization. This level of testing typically requires a functional or integrative medicine provider.
The full battery — including all Cyrex arrays, ProdromeScan, FDG-PET, CNS Vital Signs, and hormonal assessment — provides the most complete picture and allows the most precisely targeted treatment. This is the approach we use at Hippocrates Research Foundation for patients committed to a comprehensive reversal protocol.
For patients undergoing hyperbaric oxygen therapy (HBOT), timing of laboratory draws matters. Immune markers including lymphocyte subsets should ideally be drawn 48–72 hours after the most recent HBOT session to capture the optimal window of immune activation. Drawing too soon or too late may miss treatment-related changes in immune cell populations.
Given the critical role of the glymphatic system in amyloid clearance during deep sleep, a formal sleep study is essential for any Alzheimer's patient. Obstructive sleep apnea (OSA) is present in an estimated 40–70% of Alzheimer's patients — far higher than the general population — and is frequently undiagnosed. Patients and families often attribute nighttime restlessness, snoring, and daytime sleepiness to the dementia itself rather than recognizing these as symptoms of a treatable sleep disorder.
Treatment with CPAP or oral appliance therapy may meaningfully improve glymphatic clearance by restoring deep sleep architecture. Some research suggests that treating OSA can slow cognitive decline and, in some cases, produce modest cognitive improvement — likely by enhancing the brain's nightly waste disposal process. The sleep study also provides data on sleep architecture (the proportion of time spent in each sleep stage), which can reveal deficiencies in slow-wave sleep that directly correlate with reduced glymphatic function.
A simple blood or saliva test determines APOE status — whether a patient carries the APOE2, APOE3, or APOE4 alleles. This informs risk stratification, treatment intensity decisions, and safety considerations for anti-amyloid antibody therapies. APOE4 homozygotes (two copies) should be counseled that their risk of ARIA from anti-amyloid antibodies is substantially higher than average, which may influence treatment decisions. APOE4 carriers also benefit from more aggressive and earlier implementation of metabolic and lifestyle interventions.
Given the strong evidence linking P. gingivalis and periodontal disease to Alzheimer's pathology, a comprehensive periodontal evaluation — including probing depths, assessment of bone loss, and microbiological testing if available — is warranted for all patients. Active periodontal disease represents an ongoing source of both bacteria and inflammatory mediators that can reach the brain. Aggressive periodontal treatment, including scaling and root planing, antimicrobial therapy, and rigorous oral hygiene protocols, should be considered a non-negotiable component of Alzheimer's management.
Thyroid function (TSH, free T3, free T4), testosterone, estradiol, DHEA-S, pregnenolone, and cortisol should all be evaluated. Hypothyroidism — even subclinical hypothyroidism — can mimic or exacerbate cognitive decline and is readily treatable. Sex hormone deficiency in both men and women contributes to metabolic dysfunction, bone loss, muscle wasting, depression, and impaired neuroplasticity. DHEA and pregnenolone are neurosteroids with direct effects on brain function. Cortisol dysregulation — whether chronically elevated from stress or blunted from adrenal fatigue — impairs hippocampal function, the brain region most critical for memory formation.
Optimizing hormonal status does not reverse Alzheimer's by itself, but hormonal deficiency creates a metabolic environment that makes reversal more difficult. Addressing hormonal imbalances removes one more obstacle to recovery.
The optimal panel of tests for every Alzheimer's patient has not been standardized. The testing approach described in this booklet reflects current best practices in integrative and functional medicine but has not been validated in large randomized trials as a comprehensive diagnostic protocol. No medical society has issued guidelines recommending the full battery of functional medicine testing for Alzheimer's patients — though the evidence supporting individual components continues to accumulate.
Insurance coverage for many advanced panels — particularly the Cyrex arrays and ProdromeScan — remains limited. Most of these tests are paid out of pocket. The cost of comprehensive testing may range from $2,000–$5,000 depending on which panels are ordered, the laboratory used, and the treating physician's fees. Whether this investment changes clinical outcomes in a cost-effective manner is a question that deserves formal study — but for individual patients, the information gained can be transformative in directing treatment.
The sensitivity and specificity of individual Cyrex antibody markers for predicting Alzheimer's progression are still being characterized. These tests provide valuable clinical information, but interpreting borderline or isolated results requires experienced clinical judgment. Not every elevated antibody is clinically significant, and some antibodies may reflect prior exposure rather than active disease processes.
The optimal frequency of retesting has not been established. Most functional medicine practitioners recommend repeating key panels every 6–12 months to assess treatment response, but the ideal interval may vary by marker. Inflammatory markers like hs-CRP may change within weeks of intervention, while immune markers like Cyrex antibodies may take 6–12 months to reflect meaningful improvement.
FDG-PET, while extremely valuable for detecting early metabolic changes, is expensive and not universally available. Whether less expensive surrogate markers — such as blood-based measures of insulin resistance, inflammatory burden, and nutrient status — can adequately substitute for metabolic imaging in treatment monitoring is an active area of investigation.
Finally, reference ranges for many functional medicine markers are based on optimal health ranges rather than conventional laboratory reference ranges. A "normal" vitamin D level of 30 ng/mL by conventional standards may be suboptimal for neuroprotection, where levels of 60–80 ng/mL are targeted. Patients and physicians must understand that the goal is optimization, not merely avoiding clinical deficiency.
| Category | Tests | What They Reveal |
|---|---|---|
| Cognitive | MMSE, MoCA, CNS Vital Signs | Baseline severity, domain-specific deficits, treatment tracking |
| Standard Imaging | MRI (volumetric), CT | Brain structure, atrophy, vascular disease, rule out other causes |
| Advanced Imaging | FDG-PET, Amyloid PET, Tau PET, SPECT | Glucose metabolism, plaque burden, tangle burden, blood flow |
| Metabolic | Fasting insulin, HbA1c, HOMA-IR, CGM | Insulin resistance, glucose variability |
| Inflammatory | hs-CRP, homocysteine, ESR | Systemic inflammatory burden |
| Nutrient | Vitamin D, Omega-3 Index, RBC Magnesium, Cu/Zn ratio | Correctable deficiencies contributing to disease |
| Immune | Cyrex LINX, Lymphocyte MAP, Arrays 2-5, 10, 12, 20, 22 | Immune triggers, BBB status, autoimmunity, infections, gut health |
| Membrane | ProdromeScan | Plasmalogen status, membrane integrity |
| Genetic | APOE genotyping | Risk stratification, treatment personalization |
| Sleep | Polysomnography | Sleep apnea, glymphatic clearance assessment |
| Hormonal | Thyroid, testosterone, estradiol, DHEA-S, cortisol | Hormonal contributors to metabolic dysfunction |
Available at Amazon and Barnes & Noble
This booklet is intended for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making treatment decisions.
Version 1.0 — February 2026
© Hippocrates Research Foundation